Oxford Biomedica PLC - gene and cell therapy company in Oxford - Appoints Kay Davies as a non-executive director effective March 1. Davies is currently professor of genetics and co-director of Muscular Dystrophy UK Oxford Neuromuscular Centre at the University of Oxford and was co-founder of Summit Therapeutics PLC and Oxstem Ltd.
Adds Martin Diggle is to step down from the board of directors with immediate effect. Diggle joined the board in October 2012 as a non-independent director and is a founder of Vulpes Investment Management, which manages a number of funds including the Vulpes Life Sciences Testudo Fund.
"These changes further highlight our commitment to best practice corporate governance and diverse talent," says Non-Executive Chair Roch Doliveux.
Current stock price: 990.28 pence
Year-to-date change: down 3.9%
By Zoe Wickens; zoewickens@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Oxford Biomedica (OXB)